retatrutide. ESC 2024: Retatrutide improves lipid and cardiovascular risk profile in Phase II trial Buy Retatrutide (20mg) | Order

Learn more about the expertly managed $HRTS ETF on our website.

GLP-1 drugs curb appetite, but raise protein needs

Campaign for what the brand is calling the first and only GLP-1-friendly pizza included delivery of free pies.

Connect with certified providers on Meto for personalized support and results

Learn what clinical trials reveal about respiratory symptoms with Mounjaro and Zepbound, when to seek medical attention, and how to distinguish medication effects from other conditions.

Obesity has emerged as one of the leading global drivers of gastrointestinal and metabolic disease, contributing substantially to the burden of metabolic dysfunction-associated steatotic liver disease (MASLD), gastroesophageal reflux disease (GERD), Barrett's esophagus, pancreatitis, colorectal neoplasia, and obesity-associated malignancies